Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,629 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,170 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06552858 | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06548763 | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06394492 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | recruiting | Phase 3 | 440 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06544460 | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients | not yet recruiting | Phase 2 | 94 | Fudan UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06541171 | A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results(FOFU) | not yet recruiting | — | 220 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06541288 | A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer | not yet recruiting | N/A | 230 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06542549 | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | not yet recruiting | Phase 3 | 100 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT05764044 | Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer(AddChemo) | recruiting | Phase 3 | 365 | Hospital do CoracaoOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06528236 | Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass | not yet recruiting | — | 100,000 | Zhejiang Provincial People's HospitalOTHER | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06509724 | Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy(POHIM-P3) | recruiting | Phase 3 | 248 | Samsung Medical CenterOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05924776 | Plasmodium Immunotherapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 / Phase 3 | 30 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06283875 | The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer | not yet recruiting | — | 80 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06501417 | EC_ItaLynch: Mainstreaming the Diagnosis of Lynch Syndrome(EC_ItaLynch) | not yet recruiting | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06501846 | Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding.(PUG) | recruiting | N/A | 92 | Imperial College Healthcare NHS TrustOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT03386734 | International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer(SENTICOLIII) | active not recruiting | N/A | 989 | Centre Hospitalier Universitaire de BesanconOTHER | 14 | Jul 8, 2024 | clinicaltrials |
| NCT04807166 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | active not recruiting | Phase 2 | 56 | Wenjun ChengOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483425 | A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer | active not recruiting | — | 2,000 | Tongji HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06475599 | Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer | not yet recruiting | Phase 3 | 420 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05410717 | CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors | recruiting | Phase 1 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06462378 | Proton Therapy for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 55 | University of AarhusOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05876130 | Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer | recruiting | N/A | 92 | Samsung Medical CenterOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06442605 | Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy | not yet recruiting | N/A | 22 | First People's Hospital of HangzhouOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05682742 | Clinical Investigation of the da Vinci Surgical System | active not recruiting | N/A | 53 | Intuitive SurgicalINDUSTRY | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06433817 | Spectral CT in Radiotherapy for Cervical Cancer | recruiting | — | 150 | Peking Union Medical College HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06431100 | a Single-arm, Single-center, Open Clinical Study(GK-01) | recruiting | — | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06426056 | Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial. | not yet recruiting | Phase 2 | 64 | Peking University Third HospitalOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT06326294 | Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique | recruiting | N/A | 4,844 | Instituto Nacional de Saúde, MozambiqueOTHER_GOV | 1 | May 22, 2024 | clinicaltrials |
| NCT06216496 | Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer(AMINOCANCER) | recruiting | N/A | 23 | University Hospital, GrenobleOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06419673 | Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer | active not recruiting | Phase 2 | 240 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT01511328 | Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm | active not recruiting | N/A | 270,000 | Karolinska InstitutetOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06415500 | A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites | not yet recruiting | Phase 1 | 9 | Anhui Provincial HospitalOTHER_GOV | 1 | May 16, 2024 | clinicaltrials |
| NCT06417736 | Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women | recruiting | N/A | 75 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05763511 | Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker | recruiting | — | 300 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05842629 | Improved Diagnosis of Ovarian Cancer | recruiting | — | 1,700 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06404671 | Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer | recruiting | N/A | 250 | Alexandria UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05921149 | Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer | not yet recruiting | N/A | 170 | Endeavor HealthOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06251947 | Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06395844 | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06393543 | International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis(STICRISC) | not yet recruiting | — | 600 | Radboud University Medical CenterOTHER | 0 | May 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2024source: clinicaltrials